医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Alvotech Opens State-of-the-Art Biosimilar Facility in Iceland

2016年06月08日 PM10:26
このエントリーをはてなブックマークに追加


 

REYKJAVIK, Iceland

Alvotech, a powerful player in the field of biopharmaceuticals, today announces the opening of a new state-of-the-art facility, dedicated to the development and manufacturing of biosimilar monoclonal antibodies (“mAbs”). The opening of this industry leading biologics manufacturing plant marks a significant milestone for Alvotech, an independent sister company of the global pharmaceuticals company Alvogen.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160608005880/en/

Biotech facility in Iceland (Photo: Business Wire)

Biotech facility in Iceland (Photo: Business Wire)

Alvotech has worked with the U.S. FDA and European (EMA) regulatory agencies to design and build a facility complying with the highest quality standards. The manufacturing process is based on 1,000L and 2,000L single-use bioreactor fermentation design and has a total capacity of 16,000L laid out in two independent up- and downstream areas. The 13,000 square meter facility which is located in the science park of the University of Iceland in Reykjavik, also houses fully automated vial and syringe filling capabilities as well as quality control labs. Iceland offers a favorable operating environment with a strong regulatory system and a convenient geographical location.

Alvotech’s initial pipeline comprises six biosimilar mAbs which will be brought to market after patents expire. The company currently runs five offices in Iceland, Germany, Switzerland and Malta, employing almost 200 people led by a highly specialized and dedicated management team.

Eef Schimmelpennink, CEO of Alvotech said:

“At Alvotech we are committed to providing patients with more easily accessible and affordable high quality biopharmaceuticals. The opening of this new facility marks a very important milestone on this journey. Together with our robust R&D engine and our partnerships with strong commercial companies such as Alvogen, we have a truly integrated global platform. This will help to accelerate reaching our goal to establish Alvotech as one of the leading players in the biosimilar industry. “

About Alvotech

Alvotech is a powerful new player in the field of biopharmaceuticals, with a portfolio of six biosimilar monoclonal antibodies at various stages of development. Alvotech is proud to offer its biologics development and manufacturing capabilities to its partners and to cooperate in the commercialization of its biosimilar pipeline. Its state-of-the-art manufacturing facilities, contract manufacturing for biologics, in-house R&D and clinical capabilities are just a few of the many reasons why Alvotech is the partner of excellence for biosimilar initiatives. Alvotech is open for partnerships and licenses for its current biosimilar assets worldwide.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160608005880/en/

CONTACT

For Alvotech
Halldor Kristmannsson, 011 354-840-3425

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果